For those patients ineligible for allogeneic bone marrow transplant and who are non-responsive to interferon, autotransplant with peripheral blood stem cells (PBSC) mobilised after intensive chemotherapy, may provide a novel approach to improve prognosis in patients with chronic granulocytic leukaemia. PBSC harvests are assessed for CD34-positive cell numbers, which serve as an indicator of engraftment potential, and are also analysed cytogenetically to ascertain tumour cell contamination. However, a more accurate assessment of PBSC harvest contamination requires investigation of the Philadelphia (Ph) status of the CD34 pos population, in which the cells that provide long-term engraftment are contained. In this study, we have analysed these levels in mobilised PBSC and also in bone marrow (BM) harvests, taken several weeks prior to mobilising chemotherapy. Using fluorescent in situ hybridisation for the bcr/abl gene fusion, we have shown that the median number of Ph negative cells in CD34 pos isolated populations was 14.95% in BM compared to 79.05% in PBSC harvests and that in all PBSC samples tested, Ph positivity in CD34 pos populations was always detectable either by FISH or one round PCR methods. In paired assessments of both PBSC and BM harvests, higher levels of Ph negative CD34 pos cells (у14%) isolated from BM harvests, taken prior to intensive chemotherapy, correlated with higher levels of Ph negative CD34 pos cells (у78.5%) in PBSC harvests. These data may aid in the selection of patients for whom PBSC harvesting, after mobilisation, is more likely to achieve an autograft product containing predominantly Ph negative CD34 pos cells and may exclude those patients for whom the risk, morbidity and expense of stem cell harvesting may have no apparent benefit over a chronic phase BM harvest.
Introduction
Chronic granulocytic leukaemia (CGL) is a clonal myeloproliferative disorder, which arises in a pluripotential stem cell. The cytogenetic hallmark of CGL is the Philadelphia (Ph) chromosome, a truncated chromosome 22, which results from the reciprocal translocation t(9;22)(q34;q11), and its molecular characterisation is a chimaeric gene formed by the juxta-positioning of the proto-oncogene abl from chromosome 9 with the bcr gene on chromosome 22. [1] [2] [3] The resultant BCR/ABL fusion protein has increased tyrosine kinase activity and appears to play a critical role in the pathogenesis of CGL. 4, 5 Thus, the Ph fusion gene and its products are true diseasespecific markers and allow molecular tracking of leukaemic cells.
At diagnosis, greater than 95% of cells in the marrow are Ph positive. However, various lines of evidence suggest that a small pool of polyclonal, functionally competent, Ph-negative stem cells still exists (for review see Refs 6 and 7). Thus autoCorrespondence: JAE Irving, Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK; Fax: 0191-230-0651 Received 12 October 1998; accepted 3 March 1999 logous bone marrow transplantation (ABMT) and the engraftment and regenerative dynamics associated with this procedure, may tip the haemopoietic equilibrium from a leukaemic to a more normal state, whilst also reducing tumour load. Therefore, ABMT may represent an alternative therapeutic approach to improve survival for the majority of patients who are not eligible for allogeneic bone marrow transplant or are unresponsive to ␣-interferon.
Historically, autografts were performed with chronic phase bone marrow (BM) or peripheral blood and in some patients, Ph negative haemopoiesis was obtained and retained for various periods. 8, 9 However, Ph positive haemopoiesis inevitably re-emerged. Several studies suggest that autografting may prolong survival but this has not been proven by prospective randomized trials. 10, 11 Many have argued that the beneficial effects of autografting may be further improved by purging the graft of Ph-positive progenitors. In fact, a recent study suggests that Ph-positive stem cells, genetically marked in the autograft inoculum can be detected several months after autotransplant and thus may contribute to post-transplant relapse. 12 Various purging methods have been employed. In vitro methods include longterm culture of marrow and short-term incubation with mafosfamide or ␥-IFN. [13] [14] [15] Purged grafts seem to be associated with a greater frequency of cytogenetic remission post-transplant compared to unpurged grafts and it is hoped that this may translate into improved survival.
So-called in vivo purging is based on the observation that during the earliest stages of haemopoietic recovery after intensive chemotherapy, circulating progenitor cells mobilised from the marrow may be Ph negative. 16, 17 We and others have shown that peripheral blood stem cell (PBSC) harvests containing sufficient progenitors for autografting and having more than 75% Ph-negative cells, can be obtained during the early stages of CGL, in a significant proportion of patients depending on the chemotherapy regimen used. [17] [18] [19] [20] [21] PBSC harvests are assessed for CD34-positive (CD34 pos ) cell numbers, which serves as an indicator of engraftment potential and a minimum dose of 1 × 10 6 CD34 pos cells/kg has been used as the criterion for engraftment. The harvests are analysed cytogenetically and/or by interphase fluorescent in situ hybridisation (FISH) and/or by Southern blotting to ascertain tumour cell contamination. In some cases one and two round PCR methods have been required to detect any residual Phpositive cells. However, all of these methods may fail to reflect the true Ph status of the primitive progenitor cells. A more accurate assessment of PBSC harvest contamination requires investigation of the Ph status of the CD34 pos population, in which the cells that provide long-term engraftment are contained.
The aims of our study were to investigate the Ph status of the CD34 pos cells in PBSC harvests and to compare with CD34 pos cells isolated from chronic phase BM harvests, prior to intensive chemotherapy, and also to test the hypothesis that lower levels of Ph-negative CD34 pos cells in BM harvests correlate with predominantly Ph-positive PBSC harvests and may be used as a criterion for patient selection.
Materials and methods

Patients
From January 1994 the Northern Regional Group of Haematologists established a programme of chemotherapy and PBSC harvest, for those patients with CGL who were ineligible for allogeneic BMT. Thirty-two patients underwent this procedure and the results of the first 30 patients have been reported elsewhere. 21 In this present study, analysis of the CD34 pos populations was initiated at the time that patient IPN 17 entered the study. From this point onwards, we attempted to assess every BM and PBSC harvest from every patient, as far as possible. Their details are outlined in Table 1 . Sokal scores were calculated for all patients. 22 All patients were treated initially with hydroxyurea to establish a stable chronic phase. Bone marrow was harvested and cryopreserved during chronic phase, to be used if necessary for haemopoietic and immune reconstitution. Mobilising chemotherapy consisted of daunorubicin (100 mg/m 2 , day 1), vincristine (2 mg, day 1) cytosine arabinoside (100 mg/m 2 twice a day, days 1-7), all administered intravenously and prednisolone (50 mg twice a day, days 1-5) given orally. Three patients failed to achieve an adequate white cell count nadir with this regimen and a second mobilisation with highdose hydroxyurea (3.5 g/m 2 ) for 7 days was performed. Patient IPN 30 was mobilised at the first attempt with hydroxyurea because of a poor cardiac assessment.
After PBSC collections, patients were treated with interferon for 6-12 months and those patients with successful harvests, ie the target CD34 pos cell number was achieved and collections were at least 75% Ph negative, were considered for autologous transplantation. 
Ethics Committee approval
Local Ethics Committee approval was obtained for this study. Informed consent was obtained for all patients.
Leukapheresis
Leukapheresis was started when the white cell count was 0.8 × 10 9 /l and rising and continued until a target of 1 × 10 6 CD34 pos cells/kg was obtained. CD34 pos cell numbers were quantified by flow cytometry using the method of Sutherland et al. 23 Malignant cell contamination of the PBSC harvests was assessed by standard cytogenetic analysis of a target of 30 metaphases and where necessary, by RT-PCR. Isolated cells were assessed for purity by flow cytometry and consistently yielded cell purities of 94.5% ± 4.7 and 95.2 ± 5.0 (mean ± standard deviation) for BM and PBSC, respectively. Isolated CD34 pos cells, of at least 80% purity, were prepared for FISH by standard cytogenetic methods.
CD34 purification
FISH
FISH was carried out with directly labelled fluoroprobes (spectrum bcr and abl probes; Vysis, Surrey, UK) following the manufacturer's methodology. Slides were counterstained with DAPI (4Ј, 6-diamidin-2phenylindol-dihydrochloride) and examined using a standard fluorescent microscope, fitted with a triple band pass filter. 100-200 nuclei were scored. To estimate the false positive co-localisation incidence of the bcr/abl probes due to chance events, CD34 purification and FISH procedures were also performed on samples of normal BM and PBSC harvest from a lymphoma patient, in whom there was no suggestion of CGL.
RT-PCR
Total RNA was extracted from 5 × 10 5 CD34 pos cells using Qiagen RNeasy columns (Crawley, UK) according to the manufacturer's instructions. RNA was concentrated using standard precipitation techniques and taken up in a 5 l volume. All of this was reverse transcribed using random hexamers and M-MLV (Life Technologies) in the presence of RNAsin (Promega, Southampton, UK) and analysed by Multiplex PCR following the methods of Cross et al. 24 PCR products were analysed by gel electrophoresis using 3% Nusieve agarose (FMC Bioproducts, Rockland, ME, USA) and photographed after ethidium bromide staining. Positive controls consisted of K562 cells diluted 1:100 in CCRF CEM cells, expressing b3a2 transcripts and a reagent blank, containing water instead of RNA, served as a negative control.
Statistical analysis
All statistical analyses were carried out using a Prism computer programme package (GraphPad software, San Diego, CA, USA). Mann-Whitney, Wilcoxon and Spearman correlation analyses were all two-tailed.
Results
FISH analyses of purified CD34-positive populations
FISH analysis of CD34
pos populations was performed in 14 BM and 14 PBSC harvests from 17 different patients. From these 17 patients, paired samples of both BM and PBSC harvests were available for CD34 purification and FISH analysis in 11 individuals. The mean number of nuclei scored was 134 ± 51 for CD34 pos populations from BM and 167 ± 65 from PBSC harvests. The background co-localisation incidence in CD34 pos cells purified from normal BM and lymphoma PBSC samples was found to be approximately 5%.
A scatter plot comparing the percentage of Ph negative cells in CD34 pos populations in all BM and PBSC harvests is shown in Figure 1a . Numbers of CD34 pos Ph-negative cells were higher in PBSC harvests than in BM harvests. The median percentage of Ph-negative cells in the isolated CD34 pos populations was 14.95% in BM (n = 14) compared with 79.05% in PBSC harvests (n = 14) (P = 0.0163, Mann-Whitney test). Evaluations of paired BM and PBSC harvests were performed in 11 individuals; median percentage was 14.0% compared with 78.5% in BM and PBSC harvests, respectively (P = 0.0137, Wilcoxon signed rank test) (Figure 1b) .
In the paired analyses, there was a strong correlation between levels of BM Ph-negative CD34 pos cells and levels in PBSC (Spearman correlation; r = 0.8545, P = 0.0008, Figure 2 ). The six individuals who had levels of Ph-negative CD34 pos cells in their BM harvests greater than or equivalent to the median (14%), achieved levels of Ph-negative CD34 pos in their PBSC harvests which were greater than or equivalent to the median (78.5%). Of the other five patients with less than 14%, three had approximately similar levels of Ph-negative CD34 pos in PBSC harvests compared to BM, whilst the other two increased their levels to approximately 40%.
There were two patients (IPN 26 and 33) in whom mobilisation of stem cells was attempted but adequate harvested material was not obtained. Their BM CD34
pos Ph-negative scores were 33% and 16.5%, respectively. In IPN 26, the requisite number of target CD34 pos cells (1 × 10 6 /kg) was not achieved due to logistical problems, during days 3-5 of the PBSC harvest. However, cytogenetic assessment of the harvests showed minimal Ph positivity. The second patient (IPN 33) demonstrated hypersensitivity to the DOAP chemotherapy and mobilisation of CD34 pos cells was not detected.
RT-PCR of PBSC CD34-positive cells
Only two from 14 patients yielded PBSC CD34 pos populations in which no Ph-positive cells, above the background co-localisation incidence, were scored. Sufficient CD34 pos cells were available from one of these patients to perform the more sensitive technique of RT-PCR to detect residual CD34 pos leukaemic cells. Bcr/abl transcripts were readily detectable after one round PCR (data not shown), suggesting that the residual level of Ph-positive cells was in the region of 0.5-5%. Table 2 compares cytogenetic assessments of PBSC harvests to FISH analyses of the CD34 pos populations. In general, the cytogenetic results appear to reflect the FISH scores of CD34 pos cells: CD34 pos populations with minimal Ph negativity by FISH showed all positive metaphases in harvests, whilst those with the highest levels (Ͼ85%) of Ph-negative CD34 pos cells had few if any Ph-positive metaphases present in the harvest. However some results were discordant. Patients IPN 28 and IPN 31 yielded harvests in which approximately equivalent numbers of Ph-negative and Ph-positive metaphases were scored, however, analysis of the CD34 pos populations revealed levels of Ph negativity approaching 80%. These discrepancies cannot simply be explained by the wide confidence intervals, associated with scoring 30 metaphases with a proportion of 0.5, since the confidence intervals (CI) for cytogenetic analysis and FISH show no overlap, eg cytogenetic proportion 0.5, 95% CI 31.3-68.7%: FISH proportion 
Comparison of CD34 pos Ph-negative evaluations of BM and PBSC harvests with Sokal scores
Cytogenetic assessment of total PBSC harvests compared to FISH estimations of CD34-positive populations
Figure 2
Percentage of Ph-negative cells in CD34 pos populations in paired BM and PBSC harvests. 0.796, 95% CI 74.3-84.9%. In both these cases, PBSC harvests were considered poor because their cytogenetic assessment was below the target of 75% Ph negative, and yet their CD34 pos populations were 80% Ph-negative. One other case also appeared to have discrepant evaluations (IPN 29), however here the CD34 pos Ph negativity was considerably lower than the cytogenetic assessment of the whole harvest. In this case, however, the confidence intervals of the two scores do overlap (cytogenetic proportion 0.87, CI 42.6-96.2%; FISH proportion 0.385, CI 29-48%).
Figure 3
Sokal score and percentage of Ph-negative cells in CD34 pos populations in BM (a) and PBSC (b) harvests.
Discussion
Levels of Ph-negative cells in CD34 pos populations have been shown to correlate with the resultant levels of Ph-negative haemopoiesis after autotransplantation with CD34 pos isolated cells from BM and PBSC harvests. 25 Thus, FISH analysis of CD34 pos populations in PBSC harvests may be a more accurate method of assessing the quality of the transplant material. Using this approach, we show that the median number of CD34 pos Ph-negative cells in PBSC harvests was 79% (range 2.6%-94.5%) and that Ph-positive cells were detectable in CD34 pos populations of all the PBSC harvests tested, either by FISH or RT-PCR methods. The significance of this residual Ph positivity may only be elucidated when patient data after autotransplantation are available. However, genetically marked Ph-positive stem cells present in an autograft can be detected several months after transplantation, 12 thus autotransplant followed by immunomodulation with interferons or interleukin 2 may be necessary to prevent autograft-derived Ph-positive stem cells contributing to relapse. 26, 27 As might be expected, the Ph status of the CD34 pos populations of the PBSC harvests tended to reflect the cytogenetic assessment of the total harvest, however there were some discrepancies. In two patients, cytogenetic analyses of harvests implied a much higher level of Ph positivity than was apparent in the CD34 pos populations. Thus, analysis of CD34 pos populations by FISH may be a more appropriate method for assessing residual leukaemia in PBSC harvests. Whether higher levels of CD34 pos Ph-negative cells in autografts trans- Bold type represents the harvest actually used for CD34 isolations. Cytogenetic assessments of the PBSC harvests were carried out on a target of 30 metaphases, however data are also given when only 20-29 metaphases were analysed (*). F represents a failed cytogenetic assessment.
late into prolonged survival has yet to be determined. To date, we have insufficient transplant data to comment on this.
We also compared the Ph status of CD34 pos populations in chronic phase BM and in PBSC harvests. The numbers of CD34 pos Ph-negative cells was significantly higher in PBSC compared to BM harvests in both unpaired and paired analyses. In paired observations, eight of 11 patients yielded PBSC CD34 pos populations which were considerably more Ph-negative than matched BM, whilst the remainder showed no improvement in the numbers of CD34 pos Ph-negative cells after intensive chemotherapy and mobilisation. A highly significant correlation (P = 0.0008) was demonstrated between levels of BM CD34 pos Ph-negative cells and those obtained after PBSC mobilisation. Patients with levels of BM CD34 pos Ph-negative cells of 14% or above yielded high levels (Ͼ78%) of CD34 pos Ph-negative cells in PBSC harvests. A relationship between low Sokal scores and an increased likelihood of a Ph-negative PBSC harvest, has been shown by some groups 20, 21 but not others. 27 We have demonstrated an indirect correlation between Sokal scores and levels of CD34 pos Ph-negative cells in both PBSC (P = 0.0360) and BM harvests (P = 0.0306). Sokal scores, calculated at diagnosis, estimate leukaemia burden and disease status from various clinical features. However, mobilisation and PBSC harvesting may be carried out several months after diagnosis, during which time, disease progression undoubtedly occurs and it is now well recognised that successful Ph-negative PBSC mobilisations are more likely, earlier rather than later in the course of the disease. Thus, levels of Ph-negative CD34 pos cells in BM, evaluated only weeks before mobilisation might be useful in excluding a patient group for whom the risk, morbidity and expense of stem cell harvesting may have no apparent benefit over a chronic phase BM harvest and thus for these patients autografting should be performed with chronic phase BM and PBSC mobilisation not attempted. In addition, these analyses may select patients for whom PBSC harvesting is more likely to achieve an autograft product containing predominantly Phnegative CD34 pos cells. Whether, autotransplantation with predominantly Ph-negative CD34 pos cells, lengthens survival in CGL, remains to be shown.
